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Resumo 
 
 
 
Com a descoberta do sistema endocanabinóide (ECS), a sinalização 
canabinóide tem sido identificada em vários processos fisiológicos e 
patológicos. Este sistema é formado pelos recetores canabinóides
do tipo 1 e 2 (CB1 e CB2), pelos endocanabinóides anandamida 
(AEA) e 2-araquidonoilglicerol (2-AG), e pelas enzimas de síntese e 
degradação destes endocanabinóides. A sinalização 
endocanabinóide é essencial para a fertilidade, implantação e 
decidualização, e poderá também estar envolvida no 
desenvolvimento da placenta, sendo necessários mais estudos 
nesta área. O desenvolvimento da placenta é um processo 
altamente regulado e dinâmico, que envolve a proliferação, 
diferenciação e apoptose dos trofoblastos, as células especializadas 
da placenta. Este orgão, além de ser responsável pela proteção 
imune do feto, e pela troca de gases/nutrientes, desempenha um 
papel endócrino, produzindo hormonas essenciais para o 
estabelecimento e manutenção de uma gravidez saudável. Os 
endocanabinóides poderão ser um dos muitos fatores intervenientes 
na complexa regulação da produção de hormonas pelos 
trofoblastos. A cannabis é a droga mais utilizada pelas grávidas e o 
seu consumo durante a gravidez está associado a várias 
complicações nomeadamente atraso do crescimento intra-uterino e 
parto prematuro. Contudo, os mecanismos bioquímicos 
responsáveis por estas complicações estão, ainda, por desvendar. 
O principal fitocanabinóide, o Δ9- tetrahidrocanabinol (THC) poderá 
levar a um desequilíbrio da homeostasia do sistema 
endocanabinóide e da função endócrina da placenta. Com este 
trabalho pretendemos analisar qual o efeito do THC, nos 
trofoblastos, em especial na sua função endócrina. Para isso foram 
utilizados explantes de placenta e uma linha celular de trofoblastos, 
as células BeWo. Os resultados obtidos por qRT-PCR demonstram 
um aumento da transcrição de genes que codificam para a leptina, 
proteína placentária 13, progesterona e estradiol, hormonas 
essenciais para o desenvolvimento placentário e crescimento fetal. 
Foi também observado um aumento da secreção de gonadotrofina 
coriónica e estradiol. Esta desregulação hormonal poderá originar 
alterações nas vias de sinalização que regulam a proliferação, 
diferenciação e apoptose dos trofoblastos dando origem a uma 
deficiente placentação associada a complicações na gravidez. 
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Abstract 
 
 
With the discovery of the endocannabinoid system (ECS), the 
relevance of cannabinoid signaling has been recognized in several 
physiological and pathological processes including reproduction. This 
system consists of cannabinoid receptors type 1 and 2 (CB1 and 
CB2), the endocannabinoids anandamide (AEA) and 2-
arachidonoylglycerol (2-AG) and the enzymes for degradation and 
synthesis of these endocannabinoids. Cannabinoid signaling is 
essential for fertility, implantation and decidualization and possibly 
also for placental development, which is a research area that needs 
future studies. The formation and development of the placenta is a 
highly regulated and dynamic process that involves proliferation, 
differentiation and apoptosis of trophoblasts, the specialized cells of 
placenta. Besides being responsible for the immune protection of the 
fetus, and for the exchange of gases and nutrients, the placenta plays 
an endocrine role, producing hormones essential for proper 
establishment and maintenance of a healthy pregnancy. The 
endocannabinoids may be involved in the complex network that 
regulates hormone production by trophoblast cells. Cannabis is the 
drug most commonly used by pregnant women and its consumption 
during pregnancy is associated with complications, such as, 
intrauterine growth restriction and preterm delivery. Nevertheless, the 
biochemical mechanisms that lead to these complications are yet to 
be unveiled. The major phytocannabinoid, Δ9-tetrahydrocannabinol 
(THC) may have an impact in the endocannabinoid system 
homeostasis and in placenta endocrine function. With this work it was 
intended to analyze the effect of THC on trophoblasts, especially in its 
endocrine function. For this it was used placental explants and a 
trophoblast cell line, BeWo cells. Quantitative PCR results 
demonstrated an increase in the transcription of genes that encode 
hormones such as leptin, placental protein 13, progesterone and 
estradiol fundamental for placental development and fetal growth. It 
was also observed an increase in the secretion of beta-chorionic 
gonadotropin and estradiol This hormonal deregulation can have an 
impact on the signaling pathways for trophoblasts proliferation, 
differentiation and apoptosis, resulting in an incorrect placentation, 
which is associated with poor pregnancy outcomes. 
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1. Cannabinoids: an overview  
 
Cannabis sativa was one of the first plants to be cultivated in human history. 
The use of cannabis in Chinese medicine is described in Pen ts'ao ching, the oldest 
pharmacopoeia in the world, which refers to the use of cannabis in the treatment of 
intestinal problems, rheumatic pain, malaria and disorders of the female 
reproductive organs. In ancient India, cannabis was also used for medical purposes 
in the treatment of insomnia, fevers and cough (1,2). 
Nowadays, the medical use of cannabis gained its clinical relevance in the 
1990s, with the discovery of the endocannabinoid system (ECS) (3). The number of 
studies on cannabinoids has increased since then, reflecting the interest on these 
substances by the scientific community (4). Cannabinoids are ligands for 
cannabinoid receptors (cannabinoid receptor 1 – CB1 – and cannabinoid receptor 
2 – CB2), though they can also activate other types of receptors to exert their actions 
(5).  
According to their origin, cannabinoids can be divided into 3 groups (Figure 
1): phytocannabinoids, a group of cannabinoids found in Cannabis sativa, like 
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC); synthetic cannabinoids, the 
laboratory synthesized compounds, which are classified in different classes like the 
cyclohexylphenols (CP-55,940 and CP-47,497) and the aminoalkylindoles (WIN-
55,212-2, JWH-018 and JHW-073) and; endocannabinoids (eCBs) that are 
endogenous compounds, being the most representative the N-
arachidonoylethanolamine (anandamide - AEA) and 2-arachidonoyglycerol (2-AG) 
(6,7).  
The interest of cannabis and cannabinoid derivatives in the medical 
community is growing because of their therapeutic potential. This interest is 
motivated both by changes in the legal status of cannabis in many countries, by 
intense research on the role of cannabinoids and by evidence that cannabinoids 
may be useful for the treatment of various medical conditions (8). 
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 With the increased use of these compounds by the pharmaceutical industry, 
there is a need to expand cannabis plantations. This year, Portugal was the country 
chosen by Canadian and Israelite companies to cultivate and export cannabis for 
medicinal purposes. Nevertheless, in Portugal, the medical use of Cannabis sativa 
is still illegal. However, there are some approved drugs that have cannabinoids in 
their composition. In 2012, the Portuguese Authority for Medicines and Health 
Products - INFARMED, approved Sativex®, a combination of THC and CBD 
indicated to treat muscle spasticity in multiple sclerosis (9). 
 
Figure 1 - Chemical structure of some cannabinoids from different groups. 
Phytocannabinoids are a class of cannabinoids found in Cannabis sativa, like CBD and THC; 
synthetic cannabinoids are produced in laboratory such as CP-55,940, CP-47,497, WIN-55,212, 
JWH-018 and JWH-073; endocannabinoids are endogenous ligands, like AEA and 2-AG. 
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1.1. Phytocannabinoids 
 
The term phytocannabinoids represents a group of C21 terpenophenolic 
compounds found in cannabis (10). Among more than 400 compounds, 60 belong 
to the cannabinoid class, being THC, which has psychoactive effects, and CBD, 
without any psychoactive effects, the most studied (7,11,12). 
Even though it was known for years that the use of cannabis stimulates 
appetite, reduces nausea, stops seizures and relieves pain, only after the discovery 
of the structure of THC, scientists understood the clinical, biochemical and 
pharmacological effects of cannabis (13). The isolation and synthesis of THC came 
from the Israeli chemist Raphael Mechoulam in 1964 (14). Initially, the properties of 
THC were thought to be due to its lipophilic nature, so its psychotropic effects would 
result from interference in membrane fluidity rather than binding to a specific 
receptor (15). However, in the mid-1980s, several groups showed that cannabinoid 
activity was highly stereoselective, which led to the search for specific receptors and 
its endogenous ligands (7,13).  
Due to its sedative, analgesic and anti-inflammatory properties, medical 
cannabis can be used to treat nausea and vomiting-induced by chemotherapy, to 
stimulate appetite in cancer and AIDS patients, in chronic pain relief, in some types 
of epilepsy and in the control of spasticity in multiple sclerosis (16–18).  
Δ9-tetrahydrocannabinol can be extracted from the resin that is secreted by 
the plant or chemically synthesized and used for medicinal purposes. The 
concentration of THC varies according to its location in the plant: flowers, dried 
leaves or small stems have a concentration between 1% and 5%; the resin or 
hashish produced by the glands has a concentration between 5% and 10% and; the 
oil resulting from resin extraction contains a THC concentration of 50% or more 
(19,20). 
THC has the ability to stimulate dopamine release by neurons, which explains 
the sensation of euphoria (21). Its consumption may induce the onset of 
hallucinations and affect memory as it alters the way information is processed by 
the hippocampus (22,23). The use of this drug by young people can lead to long-
term problems, such as decreased memory and cognition (7). On average, its 
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effects last about two hours and start between 10 to 30 min after consumption. 
However, due to its lipophilic characteristics, accumulation of THC can occur in 
adipose tissue, extending its effects (24,25). 
 
1.2. Synthetic Cannabinoids 
 
Synthetic cannabinoids are a family of cannabinoids designed to reproduce 
specific psychotropic/therapeutic properties of cannabis. These cannabinoids 
represent the latest breakthrough in designer drugs and are synthesized through 
small variations of the THC molecule, such as esterification of the phenolic hydroxyl 
group, extending and branching of the pentyl side chain, or substituting nitrogen for 
oxygen in the benzopyran ring. These cannabinoids are sold mixed with herbs, in 
products called K2, Spice or herbal incense, without any prescription or legal 
restrictions (13,26). 
Some of the major synthetic cannabinoids found in Spice, such as JWH-018 
and CP-47,497 (Figure 1), were created by pharmaceutical companies such as 
Pfizer® for the development of analgesics. These drugs have even more potent 
effects than THC because of their higher affinity for the cannabinoid receptors. For 
this very same fact, they have been used as drugs of abuse (27–29). There are 
innumerous cases of overdose with this type of cannabinoids, reason why many 
countries are taking measures to prevent the use of these substances by adding 
them to the list of dangerous drugs (27,30). 
 
1.3. Endocannabinoids 
 
The search for endogenous ligands for the cannabinoid receptors led to the 
discovery of a family of polyunsaturated compounds derived from arachidonic acid 
that are called endocannabinoids (6). Endocannabinoids are lipid mediators that 
modulate various physiological processes by activating the cannabinoid receptors. 
The first endogenous ligand was isolated from pig brain in 1992 and named 
anandamide (31). Three years later, in 1995, a second ligand was isolated from rat 
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brain and canine gut and called 2-arachidonoyglycerol (32,33). Although other 
endogenous compounds have also been described, such as O-arachidonoyl 
ethanolamine (virodhamine) and 2-arachidonoyl glycerol ether (noladin ether), AEA 
and 2-AG are the most studied and well known eCBs (34). 
These lipid mediators may act in an autocrine or paracrine manner, mediating 
several biological processes, such as cell proliferation, differentiation, and apoptosis 
(35). Once eCBs are involved in various physiological processes, their levels must 
be tightly regulated to maintain homeostasis. These compounds are synthesized, 
on demand, through multiple biosynthesis pathways (36). Once synthesized, the 
endocannabinoids are transported in both directions through the cell membrane by 
simple diffusion due to their lipophilic nature or by a putative selective 
endocannabinoid membrane transporter (EMT) (37). Endocannabinoids may target 
the cannabinoid receptors or may act on intracellular sites of ion channels such as 
transient receptor potential vanilloid 1 (TRPV1), peroxisome proliferator-activated 
receptors (PPARs) family and T-type calcium channels (36). The cannabinoid 
signaling ends with two mechanisms that cooperate: reuptake of the eCBs and their 
enzymatic degradation. Both steps are important in the modulation of eCBs levels 
in tissues (38). There is a machinery of metabolic enzymes responsible for 
biosynthesis and degradation of eCBs, which act in a very effective way (Figure 2). 
In pathological processes, if the endocannabinoid signaling is altered, the metabolic 
enzymes are recruited to re-establish homeostasis (36).  
  
1.3.1. Anandamide 
 
As previously referred, anandamide was the first endogenous cannabinoid to 
be discovered in 1992 in the pig brain (31). Its name derives from the Sanskrit 
"ananda", which means "bliss, pleasure" and amide is due to its chemical structure 
(39). 
AEA is biosynthesized from precursors of membrane phospholipids, N-
arachidonoyl-phosphatidylethanolamines (NAPEs), resulting from the transfer of an 
arachidonoyl group from phosphatidylcholine (PC) to phosphatidylethanolamine 
(PE) by the action of N-acyl enzyme-transferase (NAT). The generated NAPE is 
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subsequently cleaved by a phospholipase D (NAPE-PLD), resulting in anandamide 
and phosphatidic acid, the latter serving as the cellular metabolic intermediate in the 
synthesis of other phosphoglycerols (34,38). After being used, AEA is mainly 
degraded by the enzyme fatty acid amide hydrolase (FAAH) that cleaves AEA into 
arachidonic acid and ethanolamine (40). 
Anandamide is a partial agonist for the CB1 receptor, whereas, as THC, it 
has a lower affinity for CB2. AEA appears as a modulator of several physiological 
functions not only in the central nervous system (CNS) but also in endocrine and 
immune system, gastrointestinal tract and reproductive organs (41,42). For 
Figure 2 - Components of the endocannabinoid system. Anandamide (AEA; green circles), 
biosynthesis from membrane precursors is catalyzed by the N-acyltransferase (NAT) followed by 
N-acyl-phosphatidylethanolamines-specific phospholipase D (NAPE-PLD). 2-
arachidonoylglycerol (2-AG; blue circles) synthesis occurs also from membrane precursors but 
through diacylglycerol lipase (DAGL). AEA is hydrolyzed by fatty acid amide hydrolase (FAAH) 
into ethanolamine (EtNH2) and arachidonic acid (AA). 2-AG is hydrolyzed through 
monoacylglycerol lipase (MAGL) or FAAH into glycerol and arachidonic acid.  
EMT - endocannabinoid membrane transporter; CB - cannabinoid receptor 
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example, in the cardiovascular system, AEA induces hypotension and bradycardia 
and, in the gastrointestinal system, inhibits smooth muscle relaxation. There also 
appears to exist a modulatory role of AEA and CB1 receptors in uterine-embryo 
interactions (43,44). 
 
1.3.2. 2-Arachidonoylglycerol 
 
2-Arachidonoylglycerol is the other major endocannabinoid that along with 
AEA influences cannabinoid signaling in the CNS and peripheral tissues. Unlike 
AEA, which has higher affinity for CB1, 2-AG is a full agonist at both CB receptors 
(45). 
The principal synthetic pathway for 2-AG is the hydrolysis of membrane 
phospholipids through a phospholipase C (PLC) producing 1,2-diacylglycerol (DAG) 
which is subsequently converted to 2-AG by diacylglycerol lipase (DAGL) (32). Once 
2-AG can trigger negative effects on certain cells and tissues, its rapid degradation 
after synthesis is essential and is ensured by monoacylglycerol lipase (MAGL), an 
enzyme that decomposes 2-AG to arachidonic acid and glycerol (46). This 
endocannabinoid seems to be important in several physiological processes, such 
as nociception, inflammation, neuroprotection, cell differentiation and apoptosis, 
and in reproductive events (36,41,47). 
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2. Cannabinoid receptors 
 
By using a radioactive THC analog, the CP55,940, it was possible in 1988 to 
identify specific binding sites of this compound in the rat brain, demonstrating the 
presence of specific receptors (48). Two years later, in 1990, Matsuda et al. cloned 
cannabinoid receptor type 1, CB1 from rat brain (3) and CB2 was cloned in 1993 
from rat macrophages (49), but it was only by the end of 2016 that CB1 crystal 
structure was reported (50) providing to the pharmaceutical industry new 
opportunities for the design of cannabinoid receptor modulators. Cannabinoid 
receptors belong to the superfamily of G protein-coupled receptors (GPCR), which 
have a seven-domain transmembrane structure. The ligands bind to the 
extracellular domain, as these receptors are found in cell membranes, and once 
activated, they signal through different transduction pathways (36). 
Generally, cannabinoids exert their effects through the stimulation of Gi/0 
protein-coupled receptor signaling inhibition of adenylyl cyclase (AC), which 
mediates the conversion of adenosine triphosphate (ATP) to cyclic AMP (cAMP), a 
second messenger that stimulates protein kinase A (PKA) activity (Figure 3). CB1 
receptor also modulates ion channels, including inhibition of N- and P/Q-type 
voltage-sensitive Ca2+ channels and activation of rectifying K+ channels. 
Additionally, activation of the CB1 receptor stimulates various intracellular kinases, 
such as extracellular signal-regulated kinase (ERK), c-jun N-terminal kinase (JNK), 
focal adhesion kinase (FAK), and p38 MAPK (p38). Yet, CB1 activation leads to 
sphingomyelin hydrolysis and acute ceramide production and accumulation. 
Although CB2 receptors also inhibit AC and produce cellular inhibition of PKA, unlike 
CB1, there is no blockade of Ca2+ channels neither activation of K+ channels. There 
are however evidences that CB2 activation involves MAPK signaling pathways and 
ceramide synthesis (51). This multiplicity of responses caused by cannabinoid 
signalling regulates critical cellular events, such as differentiation, migration, 
survival, cell death, and intracellular trafficking (36).  
CB1 are mainly located in the CNS, and in certain peripheral tissues. They 
are expressed in the hippocampus, amygdala, cerebellum, substantia nigra, basal 
ganglia and in the cerebral cortex. At the peripheral level, they are localized in the 
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lung, liver, heart, bone marrow, adrenal gland, adipose tissue, thymus, tonsils, 
prostate, uterus, ovaries and testis (52–54). CB2 is mainly found in tissues 
responsible for the production and regulation of imunne system cells, such as 
spleen, thymus and tonsils, though being also expressed in other tissues namely in 
the reproductive tract (36,52,54) . 
The knowledge of the involvement of the endocannabinoid system in various 
physiological and pathological processes, may lead to the development of new 
therapeutic approaches whether using cannabinoid receptor agonists or antagonists 
or inhibitors of endocannabinoid-related metabolic enzymes (55). 
  
Figure 3 - Cannabinoid receptor-coupled signaling pathways. Cannabinoids exert their 
effects through the stimulation of Gi/0 protein-coupled receptor signaling inhibition of adenylyl 
cyclase (AC), which mediates the conversion of adenosine triphosphate (ATP) to cyclic AMP 
(cAMP). cAMP binds to the regulatory subunits of protein kinase A (PKA). CB1 and CB2 also 
mediate ceramide accumulation involving sphingomyelin (SM) hydrolysis via sphingomyelinase 
(SMase) activation through the adaptor protein FAN (factor associated with neutral 
sphingomyelinase activation). Contrary to CB2, CB1 modulates ion channels, including inhibition 
of N- and P/Q-type voltage-sensitive Ca2+ channels and activation of rectifying K+ channels. 
Activation of CB1 can also stimulate various intracellular kinases, such as extracellular signal-
regulated kinase (ERK), c-jun N-terminal kinase (JNK), focal adhesion kinase (FAK), and p38 
MAPK (p38), being this last also activated by CB2. All these events participate in the control of 
cell function. 
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3. Cannabinoids and pregnancy 
 
Cannabinoid signaling is also involved in critical events in pregnancy such as 
gametogenesis, fertilization, oviductal transport, implantation and maintenance of 
gestation (53,56) and members of the endocannabinoid system are expressed in 
the myometrium and decidua (57,58). Moreover, in spontaneous abortions, it was 
reported an increase in CB1 receptor expression and very low levels of FAAH, as 
well as, an increase in plasmatic levels of AEA (59,60).  
Altogether it suggests that an unbalanced cannabinoid signalling may be 
involved in the pathophysiology of pregnancy related complications (Figure 4). In 
fact, there is a tight control of AEA levels both during the menstrual cycle and 
pregnancy. During follicular phase AEA levels are higher, whereas in luteal phase 
or during implantation, they are lower. These low levels of AEA are needed to 
promote uterine receptivity and maintenance of pregnancy, with a dramatic increase 
in childbirth (Figure 5) (59).  
 
Figure 4 - Deregulated endocannabinoid signaling can lead to adverse pregnancy 
outcome. Decidualization and placentation are two highly organized processes where the 
endocannabinoid system acts. Alterations in endocannabinoids levels or the expression of the 
enzymes involved in its metabolism can compromise pregnancy. Adapted from (66). 
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 Cannabinoid receptors are expressed in human oocytes and the metabolic 
enzymes of AEA, NAPE-PLD and FAAH, are localized in the follicles and in the 
corpora lutea (61) suggesting a role for eCBs in the modulation of ovarian function. 
In addition, the level of AEA in follicular fluid is correlated with oocyte maturation 
and the expression of NAPE-PLD, FAAH and cannabinoid receptors also vary 
during the menstrual cycle (53,62). 
 After fertilization, CB1 is expressed in preimplantation embryos since the 4-
cell stage until the blastocyst stage while CB2 receptor is expressed from the 1-cell 
stage to the blastocyst stage. Also, FAAH and NAPE-PLD are detected in early 
stages, showing the involvement of AEA during embryo development. In fact, it is 
 
Figure 5 - Fluctuations in AEA levels through the menstrual cycle and gestation. Under 
physiological conditions (solid line), higher AEA plasma levels in the follicular phase and lower 
concentrations in the luteal phase of the menstrual cycle, as well as at the beginning of 
implantation, are required. During early pregnancy, low levels of AEA, with respect to the levels 
measured in the luteal phase of the menstrual cycle, are needed to promote uterine receptivity 
and pregnancy maintenance. High AEA levels in the placenta at term and at the time of labor may 
be necessary for parturition. Under pathological conditions (dashed line), AEA levels are 
increased in the placenta obtained from pre-eclampsia patients, and in ectopic or non-viable 
pregnancies, as well as in lymphocytes from women who miscarry. 
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known that AEA is the key link between the development of the embryo and the 
implantation during the period of the “implantation window” (53,63).  
The endocannabinoid system also plays a role in oviductal transport. It was 
proposed that cannabinoid receptors modulate the correct transport along the 
oviduct, since in CB1 knockout animals it was observed the retention of embryos 
(63). It seems that this mechanism is only dependent on CB1, since in CB2 knockout 
animals this retention does not occur indicating that deficiencies in the CB1 receptor 
in some women may play a role in ectopic pregnancies or female infertility (Figure 
6) (64). The implantation of the blastocyst occurs 5 to 7 days after fertilization. For 
this, it is necessary that the endometrium becomes receptive after the differentiation 
of endometrial stromal cells (ESCs) into decidual cells (53). There is an uneven 
distribution of the AEA levels with a lower concentration in the implantation sites 
compared to the non-implantation sites. In what concerns FAAH, the pattern 
reverses as there is a greater expression of this enzyme at the sites of implantation 
compared to the sites of non-implantation (65). 
The decidua is a tissue that supports embryonic growth and protects the 
embryo from the mother's immune system. Decidual formation is highly regulated, 
and the endocannabinoid system members play a major role during the 
decidualization process. Pregnancy complications such as miscarriage and foetal 
growth restriction are associated with alterations in the decidualization process (66). 
In decidual cell cultures, endocannabinoids induce apoptosis, by a mechanism that 
is dependent on CB1 receptor, showing the role of ECS in the decidua regression 
(67,68).  
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3.1. Human placenta and trophoblasts 
 
The placenta, from the Greek plakuos, which means "flat cake", is a 
fetomaternal organ that separates the fetus from the endometrium (69). There are 
several studies implicating the endocannabinoid system in placental development. 
In fact, in 1999 the expression of CB receptors in term placenta was described for 
the first time (70). CB1 was found in all tissues, whereas FAAH was highly 
expressed in the decidua and amnion (71). FAAH, and both CB1 and CB2 receptors 
are also expressed in first trimester placenta (65). Moreover, CB1 knockout mice 
present an abnormal placentation (72). In addition, FAAH regulation of AEA levels 
on the placenta may play a role in fetal protection against high AEA maternal plasma 
levels (73). Concerning the other major endocannabinoid, 2-AG, it was reported the 
expression of the biosynthetic and degradative enzymes in placental 
cytotrophoblasts (74).  
Figure 6 - Regulation of endocannabinoid system throughout oviduct transport and uterus. 
Since early stages, embryo expresses CB2 and can metabolize AEA by expressing NAPE-PLD 
and FAAH. During implantation, there is a reduction of NAPE-PLD and an increase in FAHH 
resulting in reduced AEA levels. In contrast, in the inter implantation sites the AEA-metabolic 
enzymes are differentially regulated resulting in higher AEA levels. 
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During placental development the specialized epithelial-type trophoblast cells 
demonstrate invasive properties and undergo proliferation, differentiation and 
apoptosis, all processes that are essential for pregnancy maintenance (75) (Figure 
7). Abnormal placental development, either due to alterations in invasion, cell 
proliferation and differentiation or in apoptosis, can result in pregnancy 
complications such as abortion, preterm delivery, and preeclampsia, among others 
(76). Endocannabinoids were shown to intervene in cytotrophoblast apoptosis and, 
concomitantly, may have a role in placentation (43,74). 
There are two main pathways by which the stem cell cytotrophoblasts-
differentiation can occur: the extravillous and the villous pathways. From the 
extravillous pathway, there is a population of extravillous trophoblasts (EVTs) that 
acquire an invasive phenotype and differentiate into two different types: interstitial 
(iEVTs) and endovascular (enEVTs). The iEVTs invade the decidua, being involved 
in immune tolerance, and placental anchorage to the uterus, whereas enEVTs are 
involved in the remodeling of the maternal uterine spiral artery, ensuring proper 
blood flow to the placenta (77). From the villous pathway, the cytotrophoblasts (CTs) 
proliferate, differentiate and fuse to form the syncytiotrophoblasts (STs), the outer 
epithelial layer of the chorionic villi that directly contact with maternal blood. 
Syncytiotrophoblasts are involved in transport and metabolism and also produce 
hormones that are released into fetal and maternal circulation and affect fetal 
growth, metabolism and parturition (69,77,78).  
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Figure 7 - Critical steps of human placental development. (A) After implantation stems cells 
of the trophectoderm give rise to the primitive syncytium by cell fusion.  Lacunae that originate 
the intervillous space, are formed. Some of the lacunae erode uterine vessels. (B) At a 
subsequent stage, proliferative cytotrophoblasts (CTBs) emanate from the trophectoderm, break 
through the primitive syncytium and contact the basal plate thereby forming primary villi. (C) 
Tertiary villi are built upon migration of extraembryonic mesodermal cells. At distal sites, 
proliferative cell columns are formed which give rise to invasive extravillous trophoblast subtypes. 
iCTBs migrate into decidual stroma, approach vessels from outside and eventually form giant 
cells as the end stage of the invasive differentiation pathway. Endovascular trophoblasts migrate 
into spiral arteries and contribute to uNK cell-initiated remodeling within the decidua. AE, amniotic 
epithelium; CCT, cell column trophoblast; DF, decidual fibroblast; EB, embryoblast; EM, 
extraembryonic mesoderm; eCTB, endovascular cytotrophoblast; GC, giant cell; ICM, inner cell 
mass, iCTB, interstitial cytotrophoblast; LUE, luminal uterine epithelium; FALRL, lacunae, pF, 
placental fibroblast; PS, primitive syncytium; pV, placental vessel; SA, spiral artery; S, syncytium; 
TE, trophectoderm; UG, uterine gland; uNK, uterine NK cell; UV, uterine vessel; vCTB, villous 
cytotrophoblast. Adapted from (126). 
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3.2. Placenta endocrine function 
 
The placenta besides being responsible for gases and nutrients exchange, it 
provides protective immunity to the fetus and has an important endocrine function, 
producing hormones that can act at the systemic, paracrine or autocrine level, 
affecting metabolism, fetal growth and parturition (79). It is not clear the importance 
of the cannabinoids in the complex network of molecules that orchestrate the 
production of placental hormones essential for gestational success, although a few 
studies proposed a regulatory role (43,47,80,81). In this section some of the major 
placental hormones and their functions will be described. 
 
3.2.1. Human chorionic gonadotropin 
 
Human chorionic gonadotropin (hCG) is a hormone that is critical for 
establishment and maintenance of pregnancy. This hormone is a glycoprotein that 
binds to the LH-HCG receptor, which is expressed by cytotrophoblasts, 
syncytiotrophoblasts, and extravillous trophoblasts (82,83). Human chorionic 
gonadotropin can be detected in maternal plasma and urine seven days after 
conception (being urine hCG detection the most commonly used pregnancy test). 
The plasma concentration increases exponentially up to 9-12 weeks, subsequently 
decreasing to a plateau that remains stable throughout the rest of pregnancy 
(78,84).  
The syncytiotrophoblasts produces hCG, that during the first eight weeks is 
essential for the maintenance of the corpus luteum, preserving estradiol and 
progesterone secretion and, thus, preventing menstruation. When the placenta 
becomes capable of synthesizing steroids, the secretion of hCG decreases (83). 
hCG acts on the fetus, stimulating at the adrenal level the synthesis of 
dehydroepiandrosterone sulfate (DHEA-S) and, at testicular level, the synthesis of 
testosterone while in the mother inhibits the secretion of the luteinizing hormone 
(LH) by the pituitary gland. Moreover, hCG ensures that uterus maintains the optimal 
state for implantation as it acts on the decidual cells of the endometrium, preventing 
their apoptosis. In addition, promotes angiogenesis in the uterine vasculature, 
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thereby ensuring a correct blood supply and while the placenta is formed, is involved 
in the growth and development of the umbilical cord (78). hCG contributes to the 
continuous growth of the uterus, allowing the development of the fetus as it 
promotes the proliferation of smooth muscle cells of the myometrium. The 
contractility of the uterus is depressed allowing maintenance of pregnancy. During 
the last weeks of pregnancy, hCG levels tend to decrease in preparation for delivery, 
allowing uterine contractions caused by prostaglandins and oxytocin (85,86). 
The secretion of this hormone is regulated by other hormones: there is a 
stimulation by leptin, GnRH, cortisol, and an inhibition caused by progesterone and 
inhibin (83). 
 
3.2.2. Progesterone 
 
Progesterone is produced after ovulation and up to the tenth week of 
pregnancy by the corpus luteum, and then by placenta until delivery. When there is 
no fertilization, the corpus luteum degenerates, but in case of pregnancy, the 
secretion of hCG by the syncytiotrophoblasts keeps the corpus luteum, and thus the 
production of progesterone (78). 
Progesterone is produced from cholesterol. The first step requires transfer of 
cholesterol from the outer mitochondrial membrane to the inner mitochondrial 
membrane, facilitated by steroidogenic acute regulatory (StAR)-like domain of a 
protein called Metastatic Lymph Node Gene 64 Protein (MLN64), constitutive of the 
placenta (87). The conversion of cholesterol to pregnenolone is performed by the 
enzyme CYP11A being then the conversion of pregnenolone to progesterone, 
catalyzed by the enzyme 3β-hydroxysteroid dehydrogenase (3β-HSD). After 
production, progesterone is secreted into either the maternal or fetal compartment 
where it is converted in fetal adrenal steroids such as cortisol and 
dehydroepiandrosterone (DHEA) (81,88). Progesterone actions are exerted through 
binding to its receptors progesterone receptor A (PR-A) and progesterone receptor 
B (PR-B) (86). 
Known as “the pregnancy hormone”, progesterone is a major player in 
pregnancy. It has an important role in the vasodilation of uterine vessels. It is 
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involved in the rapid increase in endothelial nitric oxide synthase (eNOS) activity 
and nitric oxide (NO) production in endothelial cells (73). In early pregnancy, 
progesterone receptors are expressed in the decidual endothelial cells thereby 
having an important role during decidualization, formation of blood vessels in the 
placenta and regulating the invasion of EVTs (89). 
Progesterone decreases the contractility of the myometrium and stimulates 
the release of leukemia inhibitory factor (LIF), allowing a correct implantation and 
maintenance of pregnancy (81,88,90). Another crucial function of progesterone is 
the contribution to the development of the mammary glands, since it is associated 
with ductal proliferation and lobuloalveolar differentiation, allowing the production of 
milk after childbirth (78). Progesterone may play a role in the regulation of the 
endocannabinoid system (81,91). It inhibits the release of AEA from endothelial 
cells, and upregulates the activity and expression of FAAH in human peripheral 
lymphocytes (90,92). 
 
3.2.3. Estrogens 
 
Estrogens are steroid hormones that can diffuse through the cell membrane, 
and once inside the cell bind to specific receptors ER-alpha and ER-beta, up-
regulating several genes. The main estrogens are estrone (E1), 17β-estradiol (E2) 
and estriol (E3). Estrone is obtained from progesterone, estradiol from testosterone, 
and estriol from androsterone, being the enzyme CYP450 aromatase involved in the 
estrogen biosynthesis pathways (78,83). 
In the beginning of pregnancy, the corpus luteum is responsible for the 
production of estrogens. After five weeks of gestation as it regresses, the placenta 
becomes the main secreting organ. The levels remain low during the first trimester, 
and then increase until labor (88).  
The placenta requires steroidal precursors formed by the mother and the 
fetus to synthesize estrogens. While cholesterol, required for progesterone 
synthesis, is provided by the maternal circulation; the androgens, necessary for 
estrogen synthesis, are supplied by the fetus, since the placenta is devoid of 
17alpha-hydroxylase/17,20-lyase, essential for the synthesis of androgens. 
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Therefore, placenta uses the dehydroepiandrosterone-sulphate (DHEA-S) 
produced by maternal and fetal adrenals and synthesizes estradiol and estrone. 
Estriol is almost all synthesized at the expense of fetal precursors (83). 
Estrogenic signaling is involved in the regulation of trophoblast differentiation 
and in its invasive capacity, suggested by estrogen receptors, ERα and ERβ, 
expression in placental villous trophoblasts (93). Estrogen can regulate placental 
angiogenesis increasing the vascularity and blood vessel density in placental 
tissues (89). Besides this, it stimulates uterine growth and development of mammary 
glands, in the preparation to parturition (78). 17β-estradiol seems to be involved in 
the regulation of the endocannabinoid system (94) E2 stimulates NAPE-PLD and 
inhibits FAAH, with subsequent increase in the levels of AEA (92). 
 
3.2.4. Leptin 
 
Leptin is a peptide hormone, encoded by LEP, that is primarily secreted by 
adipocytes, having functions in weight control, appetite and energetic homeostasis, 
being also involved in thermogenesis, hematopoiesis and angiogenesis (81,83). 
This hormone has effects on several reproductive events, such as regulation of 
ovarian function, oocyte maturation, embryo development, and implantation. It is 
also produced by the placenta (95). 
Leptin has its effect mediated by its receptors (LepR) that exist in long and 
short isoforms, which couple with different signaling pathways. The long isoform, 
which mediates most of the effects of leptin, activates the JAK-STAT, ERK 1/2 and 
PI3K pathways (81). Both leptin and its receptors are located in syncytiotrophoblasts 
and endometrium (83,96). Considering that the pre-implantation embryo expresses 
LepR, and the endometrium is a target of leptin actions, there seems to be a role for 
this hormone in the blastocyst-endometrial dialogue. In fact, there is an increase of 
leptin secretion by the endometrium in the presence of a blastocyst, showing the 
importance of leptin in implantation. Leptin also stimulates the proliferation and 
survival of trophoblasts and the production of hormones thus regulating fetal growth 
and development (81,96).  
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The secretion is also regulated by other hormones during pregnancy, such 
as hCG, insulin and estradiol, which increase the synthesis of leptin, whereas 
progesterone has an inhibitory effect (83). Given its role during pregnancy, 
deregulation of the hormone's function and/or metabolism may be implicated in a 
poor pregnancy outcome, related to conditions such as intrauterine growth 
restriction, preeclampsia, recurrent miscarriage, and gestational diabetes (96). In 
relation to the endocannabinoid system, it was shown that leptin reduces the levels 
of AEA and enhances FAAH activity (97,98). 
 
3.2.5. PP13 
 
Isolated and purified from term placenta by Hans Bohn and colleagues in 
1983, placental protein 13 (PP13) is a 32 kDa protein comprised of two identical 16 
kDa subunits bounded by disulfide bonds (99). It is a member of the galectin super-
family, a family of carbohydrate-binding proteins, which are key proteins of immune-
homeostasis and inflammation, being for that, also known as galectin-13 (100). 
These proteins modulate cell adhesion, signal transduction and molecular 
recognition, by binding to β-galactoside residues on cell surfaces (101). 
 LGALS13 is the gene that encodes for PP13, and it is localized on 
chromosome 19, next to other 5 members of the super-family of galectins, and it is 
expressed in the maternal-fetal interface of the placenta (102). Although it has been 
isolated from human placenta,PP13 might be expressed in some other 
maternal/fetal tissues, during pregnancy (103). In the placenta, it is localized in the 
syncytiotrophoblast, and in the endothelium of fetal vessels. In fetal membranes, the 
PP13 gene is expressed in amnio, extravilous trophoblasts and syncytiotrophoblast 
microvillous membrane, where maternal-fetal immunological interactions occur 
(104).  
The role of this protein produced mainly by the syncytiotrophoblasts during 
pregnancy is not fully understood . When it binds to proteins of the extracellular 
matrix on the interface between placenta and endometrium, acts as a 
lysophospholipase, assisting maternal remodeling and placental implantation 
(105,106). PP13 leads cytotrophoblasts to release linoleic and arachidonic acids, 
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increasing prostacyclin and thromboxane levels, both acting as vasoactive 
prostagladins (103). For this, PP13 may have a role regulating blood pressure of the 
uterine vasculature from and to the placenta. This protein prepares the utero-
placental vessels for the needs of pregnancy, and drives the T-leukocytes to 
apoptosis, reducing the immune response to the invading trophoblasts (101). In 
addition, placental down-regulation of this gene, is associated with high risk of 
preeclampsia (107,108). 
 
3.3. Δ9-tetrahydrocannabinol and pregnancy 
 
Cannabis is the most commonly used drug by people in general, and also by 
pregnant women (109,110). As the cannabinoid signaling is tightly regulated during 
pregnancy, the use of cannabis may lead to its deregulation and, thus, to adverse 
pregnancy outcome (53).  
Although one of the functions of the placenta is to act as a barrier against 
toxins, the lipophilicity of THC allows it to cross the placental barrier, reaching the 
bloodstream of the fetus, and thereby it can affect fetal development. In fact, in 
women that had an acute consumption of cannabis, it was possible to verify the 
presence of THC in the urine 3 months after stopping its consumption (111). THC 
also passes into breast milk, thus extending the time it can harm the newborn 
(112,113). Moreover, THC can compromise fertility, since it affects follicle 
development, maturation of the oocyte, as well as the production of steroid 
hormones by the ovaries, potentially leading to deregulated/non-existent menstrual 
cycles (52,114).  
The placenta expresses the two main cannabinoid receptors and thereby 
THC may exert biological responses in placental cells. As already referred, during 
placental development stem cytotrophoblast cells undergo proliferation and 
differentiation into other trophoblast cell populations namely syncytiotrophoblasts 
and extravilous trophoblasts. In vitro studies on THC effects in BeWo cells, a 
choriocarcinoma cell line, showed a decrease in cell proliferation, although the 
mechanisms were not disclosed (115). In an extravilous trophoblast cell line, THC 
impaired trophoblast migration and invasion (116), and in term placenta trophoblast 
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primary cultures, the differentiation of cytotrophoblasts into syncytiotrophoblasts 
was also affected (117), thus interfering with a correct placentation.  
Cannabis use both before and during pregnancy is associated with several 
gestational complications. Fetuses that have been exposed to THC during 
pregnancy had lower levels of insulin, which can explain one of the common 
complications related with THC consumption during pregnancy, impaired fetal 
growth (118). Preterm birth, intrauterine growth restriction, abortion and low birth 
weight, are also associated with THC exposure (118–122). Clinical studies indicate 
that children born from mothers who consumed cannabis during pregnancy may 
experience behavioral and neurodevelopmental problems such as tremors, low 
verbal skills, poor memory, lower intelligence scores. While adults, they would have 
more propensity to be impulsive and to develop drug addiction (118). 
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4. Aims 
 
Cannabis sativa has been used for medicinal purposes for hundreds of years, 
and nowadays THC is being increasingly used in the pharmaceutical industry, in 
drug design and for treatment of various conditions. It is also known that cannabis, 
besides being the drug most consumed by the population in general, is also the 
most consumed drug by pregnant women. Cannabis use during pregnancy is 
associated with gestacional complications, such as premature delivery, low birth 
weight, and miscarriage. However, these clinical evidences are not yet perceived at 
the biochemical level and the role of cannabinoid signaling in placentation is not fully 
understood.  
Therefore, the main objective of this thesis was to study the impact of the 
main cannabinoid of cannabis plant, Δ9-tetrahydrocannabinol, in one of the most 
important functions of the placenta, the endocrine function. For that, the effects of 
THC on the production of crucial hormones to the establishment and maintenance 
of pregnancy, such as estradiol, progesterone, leptin and PP13, will be studied in 
placental explants, an accepted model for endocrine and toxicological studies, and 
also in BeWo cells, a cell line that provides a good model of placental 
cytotrophoblasts.  
This work may provide new insights into the mechanisms underlying the 
negative impact of THC during pregnancy.  
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1. Materials 
 
Dulbecco’s Modified Eagle Medium - F12 (DMEM-F12), fetal bovine serum 
(FBS), antibiotic/antimicotic solution (100 U/mL penicillin G sodium, 100 µg/mL 
streptomycin sulphate and 0.25 µg/mL amphotericin B) and trypsin were from 
Gibco/Invitrogen Corporation, CA, USA. Mouse monoclonal antibodies for 
aromatase, 3β-HSD and β-actin, and goat anti-mouse antibody were from Santa 
Cruz Biothecnology, CA, USA. The VIDAS® Progesterone, VIDAS® Estradiol II and 
VIDAS® hCG kits were from bioMérieux SA , France. RNAlater™ Stabilization 
Solution was from ThermoFisher Scientific, Waltham, MA, USA. GRS cDNA 
Synthesis MasterMix was from GRiSP Lda, Porto, Portugal. Δ9-
tetrahydrocannabinol was from Lipomed AG, Switzerland. TriSure was from Bioline 
Reagents Ltd, UK. Bradford reagent, and PCR plates were from Bio-Rad, 
Laboratories (Melville, NY, USA). SYBR™ Green was bought from Kapa 
Biosystems, MA, USA. Ethylenediaminetetraacetic acid (EDTA), diethyl 
pyrocarbonate (DEPC), isopropanol, chlorophorm, primers, cocktail of protease and 
phosphatase inhibitors, Triton X-100, activated charcoal, sulforhodamine B (SRB), 
Mayer’s haematoxylin, eosin and tetrazolium salt [3-(4,5-dimetylthiazol-2-yl)-2,5-
dipheniltetrazolium bromide] (MTT) were bought from Sigma-Aldrich Co, MO, USA. 
All plastics used in cell culture techniques were from Falcon™, SD, USA. 
Nitrocellulose membranes and ECL Prime Western Blotting Detection Reagent 
were from GE Healthcare, UK. 
 
2. Placental explants culture 
 
Placental explants are accepted as a good model for both toxicological and 
endocrine placental studies, since they hold both cytotrophoblasts and 
syncytiotrophoblasts, thus expressing all the enzymatic machinery for the 
production of hormones involved in processes related to placentation (123). Term 
placentas (n=7) of normal pregnancies (38-40 weeks gestation) of Caucasian 
women from the Porto region were collected immediately after spontaneous delivery 
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or elective cesarean section from the Centro Materno-Infantil do Norte – Centro 
Hospitalar do Porto. All procedures were conducted according to the Ethics 
Committee of the Centro Hospitalar do Porto, Porto.  
Placental explants were collected as previously described (124,125). Briefly, 
placentas were washed with saline solution to remove most of the blood. The 
placental cotyledons were then cut from at least 5 different areas of the placenta, 
and rinsed in cold DMEM-F12. After removal of the decidua, explants were obtained 
by dissecting the top layer of the villous trees and removing visible connective 
tissue, veins, and calcium deposits. All fragments, with about 30 mg of weight, were 
then washed twice with ammonium chloride, for 5 min, for removal of the red blood 
cells. After two passages per saline solution, they were allowed to stabilize in 24-
well plates (1 explant per well) for 24 h in 600 µL of DMEM-F12 with 5% 
antibiotic/antimicotic solution (100 U/mL penicillin G, 100 μg/mL streptomycin, 0. 25 
μg/mL amphotericin B) and 10% Charcoal Treated Fetal Bovine Serum (FBS-CT) 
at 37°C, 5% CO2. After 24 h, the cell culture medium from the explants was removed 
and replaced with medium at the following THC concentrations: 0, 10, 20 and 40 
µM, or vehicle (ethanol 0.01%), in the case of contols. Fetal bovine serum was 
previously treated with activated charcoal, to remove a variety of endogenous 
compounds including steroid and pepetide hormones. After treatment, the 
supernatants were collected and centrifuged at 10.000 g for 15 min, and stored at -
80 ºC, until furher hormonal measurements.Moreover, the explants were weighted 
and also stored at -80 ºC. 
 
3. Histological tissue preparation and HE 
staining 
 
For the histological studies, explants were cultured in 24-well plates and 
treated with THC for 24 and 72 h. After these treatments, the cell culture medium 
was removed, and the explants were fixed in 4% paraformaldehyde for 24 h, at room 
temperature, and then dehydrated, through increasing concentrations of ethanol 
(70, 85, 96 and 100%, 2 times 15 min), followed by 1 h on xylol, and then included 
in paraffin. Blocks were then sectioned by microtomy, and 4 µm sections were 
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collected onto glass slides. For morphological analysis it was used hematoxylin-
eosin staining. Hematoxylin is a basic dye that reacts with anionic components of 
cells and tissues, which include phosphate groups, nucleic acids, sulfate groups of 
glycosaminoglycans, and carboxyl groups of proteins. Eosin, being acidic, 
predominantly stains the cytoplasm, collagen fibers and other structures with a basic 
character. For haematoxylin and eosin staining, the slides were deparaffinized, 
hydrated, stained with Mayer’s hematoxylin solution for 4 min, washed with tap 
water, stained with 1% Eosin for 7 min, again washed with tap water, dehydrated 
through increasing concentrations of ethanol, finishing in xylene, mounted with DPX 
(Merck, MA, USA), and observed under a bright field microscope (Eclipse E400 
Nikon, Japan) equipped with image analysis NIS-Elements Documentation software 
(Nikon, Japan). 
 
4. BeWo cell culture 
 
BeWo cell line is a human choriocarcinma cell line purchased from ATCC 
(Manassas, USA). BeWo cells are widely used as a model of cytotrophoblasts, since 
these cells have the main characteristics of human cytotrophoblasts (126). 
Cells were cultured in DMEM-F12, supplemented with 10% FBS-CT, and 1% 
antibiotic-antimycotic solution, at 37°C in 95% air/5% CO2 humidified atmosphere. 
During the culture of these cells, the medium was changed every 3 days. After 
reaching 80% confluency, cells were subcultured into new culture flasks. For this, 
cells were treated with 2 mL of 0.25% trypsin/ 1 mM EDTA solution for 3 min at 
37°C, to which 2 mL of 10% FBS medium was added to inactivate trispsin. They 
were then washed with PBS, and transferred to 15 mL centrifuge tubes for further 
centrifugation, at 600 g, at 4°C for 5 min. The supernatant was then discarded, and 
the cells resuspended in culture medium, counted in a Neubauer chamber, and 
cultured at the following densities: the cells plated at 96-well plates, at 1,5x104 
cells/well (final volume 200 µL), and at 6-well plates, at 6,0x x105 cells/well (final 
volume 2000 µL). After adherence (24 h), the cell culture medium was removed and 
replaced with medium with THC at the same concentrations used for explants 
experiments or vehicle (ethanol 0.01%), in the case of controls. 
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5. Cell viability assays 
 
In order to evaluate the effects of THC on BeWo cells viability MTT and 
Sulforhodamine B (SRB) assays were performed. For this, BeWo cells were plated 
in 96-well plates. After the adhesion for 24 h, the medium was removed, and cells 
were treated with THC (0,1, 10, 20 and 40 μM) or vehicle (ethanol 0.01%), in the 
case of contols, for 24, 48 and 72 h.  
After treatment, cells were incubated with MTT (0.5 mg/mL final 
concentration) for 3 h at 37ºC in 95% air 5% CO2. After removal of the medium, 
DMSO:isopropanol mixture (3:1) was added to stop the reaction and cells were left 
for 15 min under agitation, to dissolve the formazan crystals. After this, the purple 
final solution was spectrophotometrically quantified at 540 nm, using a 
PowerWave™ microplate spectrophotometer (BioTek, WA, USA).This assay is an 
indirect measure of cell viability, once it relies on the mitochondrial metabolism to 
convert MTT (yellow) to formazan (purple).  
The SRB assay is used for cell density determination based on the 
measurement of cellular protein content. After the treatment periods, cells were fixed 
with 40% (vol/vol) trichloroacetic acid and incubated with a solution of 0.4% SRB (in 
1% acetic acid) for 20 min, after which the excess dye was removed by washing 
with 1% (vol/vol) acetic acid. Then, the protein-bound dye was dissolved in 10 mM 
Tris-base solution for O.D. determination at 492 nm using a a PowerWave™ 
microplate spectrophotometer (BioTek, WA, USA). 
 
6. RNA extraction 
 
All materials used, such as microcentrifuge tubes, tips, and water, were 
previously treated with diethyl pyrocarbonate (DEPC) to inactivate all RNAses, 
preventing RNA loss. To study the effect of THC on the transcription levels of the 
genes related to the hormones of our interest, placental explants were harvested 
after 24, 48 and 72 h of THC treatment and stored in 600 µL of RNAlater at 4°C until 
further RNA extraction. At 24 h, culture medium of the BeWo cells was removed, 
cells were washed with PBS, and 500 µL of TriSure was added to the 6-well plates, 
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and stored at -80ºC. For both explants and cells, RNA extraction was done 
according to the manufacturer's instructions. 
For RNA extraction, the explants were moved to new tubes, 500 µL of TriSure 
was added, and the tissue was homogenized using a small rotor. For BeWo RNA 
extraction, after adding 500 µL of TriSure, the cells were scraped from the bottom 
of the wells, and transferred to tubes. Hereafter, the extraction steps were the same. 
After, 100 µL of chloroform was added to the samples, the tubes were vortexed 
vigorously for approximately 15 sec, and left at room temperature for 15 min. Then, 
the samples were centrifuged at 12000 g for 15 min at 4°C. After this, the samples 
presented 3 phases: a superior, aqueous and transparent, containing the RNA; a 
whitish and viscous interface, which contains the DNA and an organic phase of 
greenish color, containing the proteins. Carefully and gently, the aqueous phase 
was transferred to a new tube, to which 250 µL of isopropranol was added, to 
precipitate the RNA. The tube was inverted 30 times, and stood for 15 min at room 
temperature. Once again the samples were centrifuged under the same conditions, 
and the supernatant was then discarded, leaving a whitish-colored pellet where the 
RNA was found. Then, for washing the pellet, 500 µL of 75% ethanol (in DEPC 
treated water) were added to the samples, which were vigorously vortexed, and 
centrifuged at 7500 g for 5 min at 4°C. Most of the ethanol was removed with a 
pipette, and the remnant was allowed to air dry. Thereafter, 20 µL of DEPC-treated 
water was added, and the RNA dissolved by pipetting the solution. After complete 
dissolution, RNA was quantified in the NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, Inc., Wilmington, DE, USA) using 1 µL of the samples, 
and RNA quality was assessed through the 260/280 and 260/230nm ratios. A 
260/280 ratio of approximately 2, and a 260/230 ratio in the range of 2.0-2.2, 
indicates that samples had no protein, phenol or other contaminants. Samples that 
went beyond these limits were discarded.  
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7. cDNA Synthesis 
 
After extraction, RNA was converted to cDNA by reverse transcription using 
the GRS cDNA Synthesis Kit (GRiSP Lda, Porto, Portugal). For each reaction, 10 
µL of GRS RT Mastermix were added, along with 1 µL of Oligo(dT)20 primer, 1 µg of 
RNA, and DEPC-H2O up to 20 µL. The samples were then placed in a thermocycler 
(BioRad, CA, USA) , as the following: 10 min at 25ºC, allowing primers to bind to 
the RNA strand, 30 min at 45 ºC, to the reverse transcriptase conversion of RNA 
into cDNA, and 5 min at 85 ºC, for the inactivation of the enzyme. The samples were 
then stored at -20 ºC until use. 
 
8. Quantitative Polymerase Chain Reaction 
(qPCR) 
 
For the preparation of the qPCR reactions, the KAPA SYBR FAST qPCR kit 
was used. To each reaction, 10 µL of KAPA SYBR FAST qPCR Mastermix, 1 µL of 
primer forward and 1 µL of primer reverse (both at 4 µM) specifically designed for 
the desired genes, 7 µL of water and 1 µL of cDNA, were added. The samples were 
then placed in the thermocycler and subjected to the following cycles of 
temperatures: 1 cycle of 3 min at 95ºC, for the activation of DNA polymerase; 40 
cycles of 3 sec at 95 °C for denaturation followed by 30 sec at the annealing 
temperature, allowing the primers to bind and the DNA polymerase to create a new 
copy of DNA. After the amplification reaction, the samples were subjected to an 
extra cycle of 5 sec, from 65 to 95ºC, with increments of 0.5ºC, to determine the 
dissociation temperature of the primers, creating the so-called melting curve. This 
curve is essential to understand if a single product has formed or if non-specific 
products have also been formed. Although all primers used were designed 
specifically for the target genes, the annealing temperatures were previously tested, 
so that only one peak was present in the melting curve, ensuring their specificity. 
The characteristics of the primers used are shown in Table 1, and GAPDH was used 
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as housekeeping gene. Relative changes in gene expression from qCR were 
analyzed trough the 2-ΔΔCT method. 
 
Table 1 - Primer sequences and qPCR conditions used to assess the expression of genes 
encoding leptin, PP13, aromatase and 3β-HSD. AT - annealing temperatura; MT - melting 
temperature; AL - amplicon lengh. 
 
 
9.  Protein extraction and Western Blot analysis 
 
After 24, 48 and 72 h of treatment, explants were transferred to 
microcentrifuge tubes and stored at -80°C. To prepare protein samples it was used 
200 µL of lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-
100) and a cocktail mix of protease and phosphatase inhibitors (both at 1:100 v/v). 
The explants were homogenized using a mini-rotor, centrifuged at 14000 g for 10 
min at 4ºC, and the supernatant was transferred to new tubes. The protein 
concentrations were further quantified by the Bradford assay.  
Protein samples (50 µg) were prepared in electrophoresis sample buffer 
(0.125 M Tris-HCl pH 6.8; 4% SDS; 20% glycerol; 10% of 2-mercaptoethanol). After 
boiling, in order to denature proteins, the samples were loaded into a SDS-
polyacrylamide (10%) gel, to perform SDS-PAGE. Proteins were then transferred 
from the gel to a nitrocellulose membrane, using Trans-Blot semi dry transfer cell, 
(BioRad, California, USA), for 50 min at 2000W. Prior to incubation with the antibody 
Gene GenBank Primer sequence (5’-3’) 
AT  
(ºC) 
MT 
(ºC) 
AL 
(bp) 
GAPDH NM_001289745.1 
F: CGCGAAGCTTGTGATCAATGG 
R: GGCAGTGATGGCATGGACTG 
55.0 83.0 358 
LEP NM_000230.2 
F: TGCGGATTCTTGTGGCTTTG 
R: CTGACTGCGTGTGTGAAATGT 
60.0 85.0 133 
LGALS13 NM_013268.2 
F: GATGGCAAACAATTTGAGC 
R: GGGATTCGATGGACAAAGCC 
54.0 88.0 98 
HSD3B1 NM_000862.2 
F: TCCACTCTTCTGTCCAGCTTTT 
R: TTCTCCTTCACCAAGAGGCG 
59.0 81.5 203 
CYP19 NM_000103.3 
F: GACGTCGCGACTCTAAATTG 
R: ACCCGGTTGTAGTAGTTGCAG 
57.3 84.5 285 
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of interest, the membrane was blocked with blocking buffer (5% dry milk in TBS with 
0.1% Tween 20), for 1 h at room temperature, in order to block non-specific binding 
sites. After that, membranes were incubated with primary mouse monoclonal 
antibodies CYP19 and 3β-HSD (1:200), overnight, at 4ºC. Then, the membranes 
were washed with TBS/Tween 20 and incubated for 1h at room temperature with an 
appropriate peroxidase-conjugated secondary antibody (goat, anti-mouse, IgG-
HRP, 1:2000). After 2 times 10 min washes with TBS/Tween 20, the membranes 
were exposed to a chemiluminescence detection reagent and analyzed using 
ChemiDoc™ MP Imaging system (Bio-Rad, California, USA). Densitometry analysis 
was performed through ImageLab software (Bio-Rad, California, USA). The 
membranes were next stripped and reincubated with anti-β-actin (mouse, 
monoclonal, 1:500) for a loading control, using a goat anti-mouse IgG-HRP 1:2000, 
as secondary antibody. As a positive control it was used a placenta microsomal 
fraction extract.  
 
10. Hormonal quantification by ELFA 
 
β-hCG, estradiol and progesterone were measured by the enzyme-linked 
fluorescence assay (ELFA), using MINI VIDAS® (bioMérieux SA , France), with the 
VIDAS® hCG, VIDAS® Progesterone and VIDAS® Estradiol II kits (bioMérieux SA 
, France). The principle of this technique associates the same immunoenzymatic 
method of known ELISA assays, with a detection by fluorescence, thereby 
increasing the sensitivity of the method. The hormones present in the medium, and 
the derivatives of hCG, estradiol and progesterone in the conjugate compete for 
antibody sites that line the interior of the solid phase receptacle. The boundless 
constituents are removed with the washing steps. During the final stage of detection, 
the substrate (4-methyl-umbelliferyl phosphate) is cycled in and out of the receptacle 
and the conjugate enzyme catalyses the hydrolysis of this substrate in a fluorescent 
product (4-methyl-umbelliderone), being then the fluorescence measured at 450 
nm. The intensity of the fluorescence is inversely proportional to the concentration 
of antigen present in the sample. Hormone levels were normalized to explant weight. 
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11. Statistical analysis 
 
All data presented are the result of at least three independent experiments, 
carried out in triplicate, and are expressed as mean ±SEM. Statistical analysis was 
carried out by ANOVA, followed by the Turkey post-hoc test for multiple 
comparisons (GraphPad PRISM v.6.0, GraphPad Software, Inc., CA, USA). Values 
of p<0.05 were considered as statistically significant.  
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III. Results
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1. THC effects on placental explants 
1.1. Analysis of explants viability 
 
In long-term cultures of placental explants, tissue viability should be 
controlled to ensure the feasibility of functional studies. The evaluation of the 
structural integrity of the explants by microscopic analysis of the morphology is one 
of the most important tests for in vitro tissue viability (127). The syncytiotrophoblasts 
are extremely susceptible to environmental conditions and easily degenerate under 
conditions commonly used in mammalian cell culture systems. For this, the first step 
in the study of the viability of the explants was to analyse paraffin sections of the 
explants stained with HE (Figure 8). Alterations such as syncytial sloughing and 
detachment, and necrosis can be easily assessed through this technique (128). 
After 72 h of culture, the explants remained viable, wihout significant morphological 
alterations, presenting a syncytiotrophoblast layer well defined.  
Figure 8 - Effects of time of incubation and THC treatment on placental explants 
morphology. Placental explants morphology was analyzed in the absense and presence of THC 
(40 µM) after 24 and 72 h of treatment. No morphological alterations were observed with time of 
incubation of THC treatment. Arrow- syncytiotrophoblast; *- Fetal blood vessel. 
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β-hCG hormone secretion analysis is another very powerful and widely used 
tool (129). As a biochemical marker of placental explants viability was assessed by 
the measurement of β-hCG secreted by the explants into cell culture medium, by 
the ELFA technique (Figure 9). 
After the incubation of the explants with THC, we found an increase in the 
levels of hormone produced after 24 h and 72 h of treatment, compared with 
controls, demonstrating that over time, explants remained viable (Figure 9). 
Hormone measurements were also performed after treatment with THC 40 µM, the 
highest concentration of THC that was used in experiments, to evaluate if this 
concentration would interfere with cell viability. Comparing the results at 24 and 72 
h, there was an increase in the production of this hormone with treatment, being this 
increase statistically significant for 72 h (p<0.05). 
 
Figure 9 - Effects of THC on β-hCG placental explants production at 24 and 72 h of treatment. 
The explants remained viable throughout the time of study, once they kept producing β-hCG. At 72 
h, there was an significant increase on hormone production at 40 µM of THC, in comparison to 
control. Significant differences between the treatment and control are denoted by * (p<0.05). 
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1.2. THC effects on endocrine function 
 
It was investigated the impact of THC in placental explants endocrine function 
concerning some of the hormones that have major influence on placental 
development by evaluating time of treatment and dose-responses. It were selected 
short and long periods of treatment and THC concentrations ranging from 10 to 40 
µM. In some cases due to lack of placental explant samples the time of 48 h 
incubation and the concentration of 20 µM were not included. 
 
1.2.1. Leptin 
 
 To investigate whether THC induces alterations in the transcription levels of 
the gene encoding leptin, LEP, qPCR was performed using cDNA samples from 
explants treated with 0, 10 and 40 µM of THC, during 24 and 72 h (Figure 10).  
The evaluation of mRNA levels revealed that placental explants treated with 
THC (10 µM) for 24 h presented a 2.4 fold increase in LEP gene transcription.  
Figure 10 - Effects of THC on the transcription levels of LEP at 24 and 72 h of treatment, 
on placental explants. THC increased gene transcription after 24 h of treatment, with THC 10 
µM, in comparison to control. Significant differences between the treatment and control are 
denoted by * (p<0.05). 
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1.2.2. Placental Protein 13 
 
In order to explore if THC induces alterations on LGALS13 transcription, the 
gene encoding PP13, explants were treated with 0, 10 and 40 µM of THC, at 24 and 
72 h of incubation and qPCR experiments were performed (Figure 11).  
The mRNA levels of PP13 were upregulated with the highest THC 
concentration, in comparison with the control, being this increase statistically 
significant at 40 µM, after 24 h of treatment. 
 
 
 
  
Figure 11 - Effects of THC on the transcription levels of LGALS13 at 24 and 72 h of 
treatment, on placental explants. Although no significant changes were observed at 72 h, THC 
led to an inscrease in gene transcription after 24 h of placental explants treatment, for 40 µM
THC, in comparison to control. Significant differences between the treatment and control are 
denoted by * (p<0.05). 
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1.2.3. Progesterone 
 
To understand the impact of THC exposure on the transcription levels of 
HSD3B1, the gene that encodes for the enzyme involved on the final step of 
progesterone biosynthesis, it was performed qPCR with specific primers for the 
enzyme using explant samples treated with THC in a concentration range between 
0 and 40 µM, and treatment times varying between 24 and 72 h (Figure 12). 
 
 
 Although no significant effect was found, with no major variations at either 
24 or 72 h, there is a tendency for an increase in gene expression with increasing 
concentrations at 48 h.  
Furthermore, the expression of 3β-HSD at protein level in placental explants 
was evaluated by Western Blot (Figure 13). Preliminary results suggest an increase 
in 3β-HSD expression in placental explants treated with 10 and 40 µM of THC, after 
48 h.  
Figure 12 - Effects of THC on the transcription levels of HSD3B1 at 24, 48 and 72 h of 
treatment, on placental explants. Although no significant results were obtained, THC seems to 
increase the transcription levels, at 48 h, in a concentration dependent-manner. 
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Moreover, the secretion of progesterone by placental explants into cell 
culture medium was also evaluated through the ELFA technique (Figure 14). 
Although no significant effect on hormonal production was found, at 72 h of 
incubation there appears to be a tendency for increased progesterone synthesis. 
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β-actin 
PC   0  10  40    0   10 40      0 10 40 [THC] µM 
Time (h) 
Figure 13 - Effects of THC on the expression levels of 3β-HSD at 24, 48 and 72 h of 
treatment, on placental explants, analyzed by western blot. Although these are preliminar 
results, expression of this enzyme seems to increase with THC treatment after 48 h of treatment, 
in accordance with the tendency found in qPCR. PC- placenta microsomal fraction extract. 
Figure 14 - Effects of THC in the secretion of progesterone by placental explants, at 24 and 
72 h of treatment. No significant changes were observed with time and THC concentrations.  
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1.2.4. Estradiol 
 
The impact of THC on the transcription levels of CYP19 encoding gene for 
aromatase, the enzyme involved on the final step of estradiol biosynthesis, was also 
evaluated. For that, qPCR with specific CYP19 primers was performed, using THC-
treated samples with concentrations between 0 and 40 µM for 24, 48 and 72 h 
(Figure 15).  
After 24 h of THC treatment, no relevant effects were observed. At higher 
concentrations and times, CYP19 transcription was increased by THC, being this 
statiscally significant for 40 µM, at 48 h (Figure 15).  
The expression of aromatase at the protein level was also evaluated through 
Western blot (Figure 16). 
Figure 15 - Effects of THC on the transcription levels of CYP19 at 24, 48 and 72 h of 
treatment, on placental explants. THC, at 40 µM, after 48 h, led to a significant increase in the 
transcription of the gene that encodes for aromatase. Significant differences between the 
treatment and control are denoted by * (p<0.05). 
45 
 
 
 
Figure 16 - Effects of THC on the expression levels of aromatase assessed by western blot at 
24, 48 and 72 h of treatment, on placental explants. A - Representative western blot. B – 
Densitometry analysis considering 3 different experiments. At 72 h, at 10 and 40 µM of THC led to 
an increase of the aromatase expression. Significant differences between the treatment and control 
are denoted by * (p<0.05). PC- placenta microsomal fraction extract. 
 
 
THC treatments did not lead to major alterations in aromatase expression at 
24 and 48 h. However, at 72 h, the expression of this enzyme had a significant 
increase, either at 10 and 40 µM of THC. 
Furthermore, the endocrine function of placental explants, regarding to 
estradiol synthesis was studied. For this, released estradiol into the culture medium, 
was quantified through ELFA (Figure 17). 
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Figure 17 - Effects of THC on the secretion of estradiol by placental explants, at 24 and 72 h 
of treatment. After 72 h, at concentration of 40 µM, THC enhances estradiol. Significant differences 
between the treatment and control are denoted by * (p<0.05) 
 
Although at 24 h there is no significant changes in estradiol production, at 72 
h, THC appears to stimulate the production of estradiol in a concentration-
dependent manner, being this increase statistically significant. 
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2. THC effects on BeWo cells 
 
In addition to the studies on placental explants that hold both 
cytotrophoblasts and syncytiotrophoblasts, it was also investigated the impact of 
THC in BeWo cells, a widely used model of cytotrophoblast cells. It was first 
analysed the effects of THC in cell viability by the MTT and SRB assays, followed 
by the evaluation of the effects on the endocrine function at the selected conditions.  
  
2.1. Analysis of BeWo cells viability 
 
To evaluate the effects of THC on BeWo cells viability, cells were plated in 
96-well plates with THC concentrations ranging between 0 and 40 µM for 24, 48 and 
72 h, and MTT and SRB assays were performed (Figure 18). 
Figure 18 - Effects of THC on BeWo cells viability by MTT assay. Significant enhanced MTT 
metabolism was observed for THC at 40 µM, after 24 h treatment, and at 10 µM, after 72 h of 
incubation. Significant differences between the treatment and control are denoted by * (p<0.05). 
 
At lower concentrations THC had no impact on cell viability. However, for the 
concentration of 40 µM at 24 h and 10 µM at 72 h, a significant increase in MTT 
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metabolism was observed. Since the MTT assay is based on mitochondrial enzyme 
activity, thus, an indirect method to measure cell viability, another method was used, 
the sulforhodamine B (SRB) assay, which measures the protein content of the cells 
(Figure 19). 
Figure 19 - Effects of THC on BeWo cells viability by SRB assay. A significant decrease in protein 
content was observed at 48 and 72 h of THC treatment, both for 40 µM concentration. Significant 
differences between the treatment and control are denoted by * (p<0.05). 
 
 
The effect observed on MTT assay was different from the SRB assay results. 
Distintly, no differences were observed for 40 µM at 24 h and 10 µM at 72 h in SRB 
assay, suggesting that THC may affect mitochondrial activity, without inducing cell 
proliferation. By the SRB assay, it was possible to detect, for 40 µM, at 48 and 72 
h, a decrease on SRB, suggesting a decreased cell number (Figure 19). Therefore 
the time of 24 h treatment was selected for the following experiments on THC effects 
on BeWo cells endocrine function. 
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2.2. THC effects on endocrine function 
 
2.2.1. Placental Protein 13 
 
BeWo cells express LGALS13 gene, reason why it was also studied the effect 
of THC in PP13 expression. For this, qPCR was performed using cDNA samples of 
BeWo cells treated with 0, 10, 20 and 40 µM of THC, for 24 h (Figure 20).  
Figure 20 - Effects of THC on the transcription levels of LGALS13 at 24 h of treatment on 
BeWo cells. THC causes an upregulation of the PP13 gene, being this increase statistically 
significant at 40 µM. Significant increase in the transcription between the treatment and control are 
denoted by * (p<0.05). 
 
After 24 h of treatment, LGALS13 transcription appears to increase along 
with THC concentration, in comparison with the control, being this increase 
statistically significant at 40 µM (Figure 20). 
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2.2.2. Progesterone 
 
Similarly, the gene that encodes for the enzyme of the final step of 
progesterone biosynthesis, 3β-HSD, was studied in response to THC. For this, 
qPCR with HSD3B1 specific primers was performed for cDNA samples of BeWo 
cells treated with 0, 10, 20 and 40 µM of THC, for 24 h (Figure 21). 
Figure 21 - Effects of THC on the transcription levels of HSD3B1 at 24 h of treatment on BeWo 
cells. Higher treatment doses of THC increases the transcription levels of this gene, being this 
increase statistically significant at 40 µM. Significant differences between the treatment and control 
are denoted by * (p<0.05). 
 
Also HSD3B1 transcription increases with THC after 24 h of treatment, being 
statistically significant at 40 µM.  
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2.2.3. Estradiol 
 
THC impact on the expression of CYP19, the gene that encodes aromatase, 
was also assessed by qPCR (Figure 22).  
Figure 22 - Effects of THC on the transcription levels of CYP19 at 24 h of treatment on BeWo 
cells. A statistically significant increase at 40 µM (p<0.05), was also assessed for THC treatment. 
Significant differences between the treatment and control are denoted by * (p<0.05). 
 
Also, in this case it was observed an increase in CYP19 gene transcription with 
THC treatment, being statistically significant at 40 µM.  
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IV. Discussion
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The placenta besides being responsible for exchange of nutrients and gases 
and fetal protection, has also an important endocrine function as it produces a wide 
number of hormones that play essential roles in the establishment and maintenance 
of pregnancy (130). The specialized epithelial-type trophoblast cells of the placenta, 
are divided in various subtypes namely cytotrophoblasts, syncytiotrophoblasts and 
extravilous trophoblasts (131,132). In this work it was emplyed term placental villous 
explants, widely used as a model to study transport, metabolism and hormone 
production at the maternal-fetal interface. Explants contain several cell types 
besides trophoblasts, like mesenchymal stroma cells, endothelial cells, and 
placental immune cells. The main advantage of the explants model is that the 
trophoblast is conditioned by co-culture with other cells thus allowing experimental 
conditions that more closely mimic placental environment. In contrast, the 
choriocarcinoma cell lines such as BeWo cell line is well-accepted as a 
cytrophoblast cell model and represents a suitable and simple system for studying 
trophoblast cells turnover. 
During placental development, trophoblast cells undergo tightly regulated 
processes of proliferation, differentiation and apoptosis (133). Cytotrophoblasts 
behave as stem cells for the other types. Proliferation of cytotrophoblasts is followed 
by differentiation and fusion into syncytiotrophoblasts being these processes 
regulated by lipids, fusogenic proteins (syncitin-1, syncitin-2), growth factors and 
hormones (134). Regulation of cytotrophoblast apoptosis is also involved in 
syncytium formation. The balance between proliferation differentiation and 
apoptosis is the key to normal placental development and alterations in this delicate 
turnover may lead to pregnancy complications. These processes are under control 
of various cytokines and growth factors, and endocannabinoids may play a role in 
this complex network of modulators. In fact, cannabinoid signaling is involved in 
cytotrophoblast cell apoptosis (43,74) and differentiation (47,80) and the 
endocannabinoid system members are expressed in placental tissues from early 
gestation to labor (66).The intake of exogenous cannabinoids can cause 
disturbances in both cannabinoid signaling and in the endocannabinoid system 
homeostasis, affecting placentation and placental functions. Cannabis sativa is the 
most consumed illicit drug by pregnant women (109) but few studies have examined 
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the effects of cannabinoid consumption on placental developmentl. Clinical 
evidences such as decreased gestational length, preterm birth and poor pregnancy 
outcome have been associated with cannabis use (135). However, the biochemical 
mechanisms underlying these effects are unknown. In vitro studies indicate that Δ9-
THC interferes with trophoblast invasion (116), proliferation and turnover (117), 
which may negatively impact placentation. Besides THC interferes with nutrient 
transport across the placenta affecting folic acid uptake in chronic exposure to THC 
(136). However, the impact of cannabis use in one of the most important placental 
functions, the endocrine function is poorly understood. 
In the current study, it is demonstrated that THC affects placental hormone 
production. THC treatment led to an increase in hCG levels in explants culture 
medium with time of treatment. This hormone stimulates adenylyl cyclase, and 
increase cAMP levels thus promoting cytotrophoblast differentiation (131). 
Interestingly, this phytocannabinoid appears to have an opposite effect to either 2-
AG or AEA (47,80). Primary syncytiotrophoblast cells exposure to AEA, results in 
decreased secretion of hCG, diminished expression of aromatase, leptin and PP13, 
having no effect on 3β-HSD gene expression. In contrast, 2-AG reduces hCG 
secretion and transcription of genes encoding leptin, aromatase, and PP13, 
enhancing 3β-HSD transcription. Moreover, the results of this thesis show that THC 
leads to increased PP13 and leptin gene transcription. PP13 is expressed 
predominantly by the syncytiotrophoblast, from where it is released into the maternal 
blood. PP13 plays a role in the regulation of vascular remodeling and in the 
promotion of a tolerogenic environment that facilitates trophoblast invasion mostly 
as it has a pro-apoptotic effect on activated decidual T cells, critical in the down-
regulation of maternal immune responses (102). Moreover, the pro-inflammatory 
actions of this hormone may also play a role in early placentation events. In fact, 
decidua is infiltrated by natural killer cells, and macrophages that produce cytokines, 
matrix metalloproteinases and angiogenic factors that regulate trophoblast invasion 
and uterine spiral artery remodeling. So, these immune cells besides being involved 
in the establishment of the immune tolerance promote local pro-inflammatory 
responses that facilitate implantation, trophoblast invasion and placentation (137). 
In fact, in the second and third trimesters, maternal serum PP13 concentrations rise 
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paralleling the escalation in the physiological maternal systemic inflammation. In 
preeclampsia, the abnormal ischemic placental stress and pro-inflammatory 
changes at the maternal-fetal interface are also reflected by the increased maternal 
blood PP13 concentrations compared to normal pregnancy. As a consequence, 
PP13 has a good diagnostic value for the diagnosis of preeclampsia (138). In 
addition, PP13 is involved in the differentiation and syncialization of trophoblasts. In 
vitro assays with BeWo cells demonstrated that LGALS13 expression is related to 
trophoblast fusion and syncytium formation induced by the cAMP-analogue 
Forskolin and that a PKA inhibitor could inhibit LGALS13 expression (126). Another 
study in primary trophoblast cells confirmed these findings and demonstrated a 
relation between syncialization and differentiation and LGALS13 expression (139). 
The results of this thesis demonstrate an increase in LGALS13 expression that may 
reflect alterations in cytotrophoblast differenciation occurring in both explants and 
BeWo cells under THC action, especially when used in high concentrations. 
Dysregulation of leptin metabolism and/or function in the placenta may be 
implicated in the pathogenesis of various disorders during pregnancy, such as 
recurrent miscarriage, intrauterine growth retardation, and preeclampsia. In fact, 
leptin gene expression in the placenta is increased in preeclampsia, and maternal 
plasma leptin levels are higher than those in normotensive pregnant women. 
Furthermore, leptin may play a role in implantation due to its stimulatory effect on 
matrix metalloproteinase expression (140). 
The results show an increase in LEP mRNA levels. This hormone may 
stimulate the proliferation and survival of trophoblasts (81,86). In addition, it has 
pleotropic effects in trophoblast cells, once enhances hCG production, and 
decreases progesterone and estradiol biosynthesis (141,142). Leptin effects are 
due to the activation of JAK-STAT, ERK 1/ 2 and PI3K pathways (143). On the other 
hand, the complex regulation of leptin production in the placenta is still poorly 
understood. Previous works demonstrated that hCG and cAMP enhances leptin 
expression through a crosstalk between PKA and MAPK signaling pathways 
(144,145) and that 17β-estradiol up-regulates placental leptin expression (146). 
Moreover, the results of this thesis indicate an increase in estradiol levels with THC 
treatment that can contribute to leptin mRNA increased levels observed in explant 
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cultures. In fact, the synthesis of leptin may also depend on estrogen regulation as 
we observed a decrease in LEP gene transcription and β-hCG secretion after THC 
treatment in primary trophoblast cultures a simple model lacking the trophoblast 
turnover involving proliferation, differentiation and apoptosis (117). 
Human placenta is known to synthesize estrogens during pregnancy in 
association with the cytotrophoblast invasion. There is evidence to suggest that 
placental derived estrogen may play an autocrine role in trophoblast differentiation 
(147,148). This steroid hormone enhances cytotrophoblast syncialization via ERα 
(149). Estradiol biosynthesis is enhanced by cAMP, hCG, p38 phosphorylation and 
ERK 1/ 2 inhibition (47,150,151). In our case, the studied phytocannabinoid 
demonstrated a regulatory effect on estradiol secretion and induced aromatase 
expression by the cultured explants and the transcription of aromatase encoding 
gene in either explants and BeWo cells. Supporting these results, the increase in 
estradiol production was also observed in animal studies that showed that high 
doses of Δ9-THC-like drugs increased LH and estrogen in pregnant rats (152). 
Moreover, Rhesus monkeys who received Δ9-THC had significantly elevated 
estrogen levels compared with vehicle controls (153). Just as the endocannabinoid 
AEA, THC seems to have no significant effect on the expression of the gene 
encoding for 3β-HSD, nor at protein expression level, neither in progesterone 
secretion in the explants contrary to the observed increase in BeWo cells indicating 
that it is important to increase the number of placental samples for statistical power. 
Progesterone production by the placenta is regulated by numerous factors. While 
leptin inhibits the production of progesterone by syncytiotrophoblasts, PKA and 
estradiol stimulate progesterone synthesis (154,155). Also, p38 and ERK 1/ 2 
phosphorylation increase the transcription of the gene encoding 3β-HSD (47). 
A previous study from our group showed that THC has a dual effect on 
primary cytotrophoblast cultures. At lower concentrations, THC increased MTT 
metabolism and revealed an antioxidant capability, while at higher concentrations, 
THC decreased cell viability (117). In our study, the metabolism of MTT by BeWo 
cells was significantly increased at 24 h for 40 μM treatment and at 72 h for 10 μM 
concentration. Under the same conditions, the whole-cell protein content as 
reflected by the SRB test was not significantly altered, suggesting that THC may 
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prevent cell death and enhance mitochondrial activity. In what concerns endocrine 
function, at 24 h treatment, THC induced an upregulation of all genes studied in 
BeWo cells, whereas this effect was only found for explants at later times. 
With this work, and in general, we have demonstrated that THC affects 
placental endocrine function. All hormones studied, except for the case of 
progesterone, suffered significant variations at either mRNA, protein or hormone 
secretion levels. It was observed an increase in progesterone secretion, though not 
statistically significant. A higher number of studied placentas would be necessary to 
comprehend these results. This hormonal deregulation caused by the consumption 
of THC may interfere with cellular processes of proliferation, differentiation and 
apoptosis. The hormones produced by the placenta regulate implantation, 
placentation, vascular remodeling and childbirth. However, the direct involvement 
of each of the hormones produced by the placenta during pregnancy is not 
demonstrated, since they are highly regulated by several factors, including by other 
hormones in a complex network of interactions (Figure 23). Nevertheless, 
deregulation in the balance of these hormones can have a negative impact on any 
of these steps, leading to pregnancy complications, such as miscarriage, preterm 
labor, intra-uterine growth restriction, all conditions associated with cannabis 
consumption during pregnancy. In addition, THC may also affect the 
endocannabinoid system homeostasis and thus indirectly deregulate placental 
hormone secretion adding complexity to the signaling pathways involved in THC 
actions. 
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Figure 23 - A model for illustrating THC effects on trophoblast endocrine function. THC 
causes upregulation of genes responsible for encoding hormones such as PP13, leptin, 
progesterone and estradiol. The regulation of these hormones affect the synthesis of others, and 
activate signalling pathways, responsible for cell proliferation, differentiation and apoptosis. Also 
THC enhances MTT metabolism, increases ATP production and diminishes ROS/RNS 
generation. 
59 
 
Final conclusions 
 
The study developed during this master's thesis describes the impact of the 
main psychoactive compound of Cannabis sativa, THC, on endocrine placental 
function. Previous studies suggest that THC may alter trophoblast cell proliferation, 
differentiation and invasion. This work reveals that THC can affect placental 
hormone secretion by increasing transcription of the genes encoding PP13, leptin, 
aromatase and 3β-HSD. Moreover, THC stimulates estradiol and β-hCG secretion. 
This hormonal dysregulation can have an impact on the signaling pathways for 
trophoblasts proliferation, differentiation and apoptosis, resulting in an incorrect 
placentation, which is associated with poor pregnancy outcomes, conditions 
associated with cannabis consumption during gestation. 
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